GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Krebs Biochemicals & Industries Ltd-$

Krebs Biochemicals & Industries Ltd. Board Approves Amalgamation Scheme with Ipca Laboratories

BOARD ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 26 Jun 2026, 01:11 PM IST  ·  BSE ID: c4ccb3b6-24df-4d5e-95fe-6c19c8dde606
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board has agreed to merge Krebs Biochemicals & Industries Ltd. with Ipca Laboratories Ltd., pending necessary approvals.
🤖 AI Summary
  • Board approved Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories Ltd.
  • Scheme is subject to approvals under Companies Act, 2013 and SEBI LODR Regulations.
  • Appointed date for the Scheme of Amalgamation is 1st April, 2026.
  • Amalgamation details were disclosed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Appointed Date for the Scheme
1st April, 2026
🏢 How This Affects the Company
📈
Business Impact
The amalgamation will lead to the combination of Krebs Biochemicals & Industries Limited into Ipca Laboratories Limited, altering its corporate structure and future business operations under the transferee entity.
💰
Financial Impact
Financial statements of Krebs Biochemicals & Industries Limited will be consolidated into Ipca Laboratories Limited, impacting the latter's balance sheet and financial performance metrics upon completion of the scheme.
⚙️
Operational Impact
Operational integration and potential restructuring will occur as Krebs Biochemicals & Industries Limited ceases to operate as a separate entity and becomes part of Ipca Laboratories Limited.
⚠️
Risk Impact
Regulatory and integration risks are inherent in any amalgamation process, with successful completion dependent on securing all necessary approvals from relevant authorities.
👥 What This Means For Shareholders
✅
Action Required
Shareholders should monitor future announcements regarding the progress of regulatory approvals and the effective date of the amalgamation.
👤
Who Is Affected
All shareholders of Krebs Biochemicals & Industries Limited are affected by this decision, as their shareholding will be subsumed into Ipca Laboratories Limited upon scheme completion.
🔍
Management Signal
The board's approval signals management's intent to proceed with a significant corporate restructuring and integration.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Status of SEBI and Companies Act, 2013 approvals
Effective date announcement post-approvals
Details of share swap ratio, if applicable
MEDIUM RISK Amalgamation completion depends on multiple regulatory approvals, introducing execution risk.
💡 Investor Takeaway
Krebs Biochemicals & Industries Ltd. board approved an amalgamation scheme with Ipca Laboratories Ltd., effective from 1st April, 2026, pending regulatory approvals. This marks a significant corporate event for the company.
⚖️ Strengths & Concerns

✅ Positives

  • Board-level approval signifies a concrete step towards the amalgamation with a larger entity.
  • Scheme approved under Companies Act, 2013 and SEBI LODR Regulations, indicating adherence to legal frameworks.
❓ Frequently Asked Questions
What decision did the Board of Krebs Biochemicals & Industries Ltd. make?
The Board approved the Scheme of Amalgamation of Krebs Biochemicals & Industries Limited with Ipca Laboratories Limited.
When is the appointed date for the Scheme of Amalgamation?
The appointed date for the Scheme of Amalgamation is 1st April, 2026.
What approvals are required for the amalgamation to be effective?
The Scheme is subject to necessary approvals under the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Which companies are involved in the amalgamation?
Krebs Biochemicals & Industries Limited is the Transferor Company, and Ipca Laboratories Limited is the Transferee Company.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.